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ABSTRACT
Background: Due to the lack of specific clinical manifesta-
tions and imaging features, the diagnosis of pulmonary myco-
sis is difficult. This study aimed to investigate the pathogens,
clinical manifestations, imaging features, diagnosis and man-
agement of pulmonary mycosis. 
Methods: Data on 68 patients diagnosed as pulmonary myco-
sis in Xiang Ya hospital from January 2001 to December 2010
were collected and their clinical manifestations, radiographic
characterization, diagnostic methods and management were
analyzed. 
Results: All patients were diagnosed by pathological examina-
tion. Of the 68 cases, 38 (55.9%) had pulmonary aspergillosis
and 19 (27.9%) pulmonary cryptococcosis. Open-lung sur-
gery was performed in 38 patients (55.9%), transbronchial
biopsy in 15 (22.0%), and computerized tomography (CT)-
guided percutaneous needle biopsy in 11 (16.2%). Main
symptoms were as follows: cough in 51 cases (75.0%), expec-
toration in 38 (55.9%), hemoptysis in 25 (37.8%), fever in 20
(29.4%), while 6 cases (11.1%) were asymptomatic. X-ray
and chest CT showed masses or nodular lesions in 52 cases
(76.5%), patchy lesions in 10 (14.7%), cavity formation in 15
(22.0%), and diffuse miliary nodules in 1 case. In 51 cases
(75.0%) misdiagnosis before pathological examination
occurred. Surgical resection was performed in 38 patients
(55.9%). In 25 patients (36.7%) systemic antifungal therapy
was administered, and 20 patients (29.4%) experienced com-
plete responses or partial responses. 
Conclusion: The main pathogens of pulmonary mycosis are
Aspergillus, followed by cryptococcosis. Final diagnosis of pul-
monary mycosis mainly depends on pathological examina-
tion. The clinical manifestations, imaging features, diagnostic
methods and management differ depending on the
pathogens. Satisfactory therapy can be obtained by both
antifungal and surgical treatment.
Keywords: Clinical manifestations, imaging features, pul-
monary mycosis.
RIASSUNTO 
Razionale: La diagnosi di micosi polmonare è resa difficile dal-
la mancanza di manifestazioni cliniche specifiche e di imma-
gini patognomoniche. Questo studio ha lo scopo di valutare
patogenesi, manifestazioni cliniche, caratteristiche radiologi-
che, diagnosi e gestione delle micosi polmonari.
Metodi: Sono stati raccolti i dati di 68 pazienti con diagnosi di
micosi polmonare nell’ospedale di Xiang Ya (Cina) tra gennaio
2001 e dicembre 2010; sono state analizzate le manifestazio-
ni cliniche, la caratterizzazione radiologica, le metodologie
diagnostiche e la gestione. 
Risultati: In tutti i pazienti è stata posta una diagnosi anatomo-
patologica. Dei 68 casi 38 (55,9%) presentavano un’aspergillosi
polmonare e 19 (27,9%) una criptococcosi polmonare. La chirur-
gia a cielo aperto è stata effettuata in 38 pazienti (55,9%), una
biopsia transbronchiale in 15 (22,0%) ed una biopsia con ago
sottile per via percutanea TAC-guidata in 11 (16,2%). Questi i
sintomi principali: tosse in 51 casi (75,0%), espettorazione in 38
(55,9%), emottisi in 25 (37,8%), febbre in 20 (29,4%), mentre 6
casi (11,1%) erano asintomatici. Alla Rx e alla TAC torace si rile-
vavano masse o lesioni nodulari in 52 casi (76,5%), opacità irre-
golari in 10 (14,7%), formazioni escavate in 15 (2,0%) e noduli
miliari diffusi in 1 caso. In 51 casi (75,0%) prima della valutazio-
ne anatomo-patologica i pazienti avevano ricevuto una diagnosi
errata. È stata effettuata una resezione chirurgica in 38 pazienti
(55,9%). In 25 pazienti (36,7%) è stata somministrata una tera-
pia antifungina per via sistemica e 20 pazienti (29,4%) hanno
ottenuto una risposta completa o parziale. 
Conclusioni: L’agente patogeno principale delle micosi pol-
monari è stato l’Aspergillus, seguito dalla criptococcosi. La
diagnosi definitiva necessita prevalentemente del dato ana-
tomo-patologico. 
Le manifestazioni cliniche, radiologiche, i metodi diagnostici
e la gestione dipendono dal tipo di patogeno. Un trattamen-
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to soddisfacente può essere ottenuto sia con la terapia anti-
micotica che con un intervento chirurgico.
Parole chiave: Imaging, manifestazioni cliniche, micosi polmo-
nare.    
The incidence of pulmonary mycosis has increased
over the past few decades due to the wide use of
broad-spectrum antibiotics, immunosuppressive
and chemotherapy agents as well as the increased
incidence of respiratory diseases, including chronic
obstructive pulmonary disease (COPD), lung cancer
and tuberculosis [1]. It has been reported that the
overall incidence of systemic fungal infection is up
to 11.3% and 60% of them involve the bronchi and
lungs at autopsy [2]. However, due to the lack of
specific clinical manifestations and imaging fea-
tures, the diagnosis of pulmonary mycosis is diffi-
cult. In order to further investigate the pathogenesis,
clinical manifestations, prognosis and the risk fac-
tors of pulmonary mycosis, we performed a retro-
spective analysis of patients with pathologically
confirmed pulmonary mycosis from a single institu-




From January 2001 to December 2010, 68 patients
were diagnosed as pulmonary mycosis by patholog-
ical examination at the Xiang Ya Hospital (Hunan,
China). All cases met the diagnostic criteria involv-
ing clinical, microbiological and radiological
analyses [3,4]. The study was approved by the
Ethics Committee of Xiang Ya Hospital and all pa-
tients gave their informed consent.
Treatment efficacy evaluation 
The overall response to treatment was defined ac-
cording to specific criteria [3,4]. ‘Complete response’
was defined as the disappearance of all symptoms,
signs and radiographic or bronchoscopic abnormali-
ties present at the enrollment. ‘Partial response’ was
defined as a major improvement. ‘Stable disease’ was
considered to be minor or no improvement, but with-
out deterioration. ‘Progressing disease’ was defined
as new disease sites or original disease worsened.
‘Failure’ was defined as a deterioration necessitating
alternative antifungal therapy or resulting in death.
Drug safety assessments 
Each patient was evaluated for adverse events.
Adverse events and laboratory abnormalities were
recorded, which included hematology, blood bio-
chemistry, and urine analysis. 
Statistical analysis 
Data among different groups were analyzed by χ2
test using the SPSS 16.0 statistical package. A p val-
ue < 0.05 was considered statistically significant.
RESULTS 
Etiology
Among the 68 patients, 38 cases (55.9%) were
identified as pulmonary aspergillosis, 19 (27.9%) as
pulmonary cryptococcosis, 5 (7.4%) as pulmonary
candidiasis, 4 (5.8%) as pulmonary histoplasmosis,
1 (1.5%) as pulmonary sporotrichosis and 1 (1.5%)
as actinomyces pneumonia.
Demographics
Of the 68 patients, 41 (63.0%) were males and 27
(37.0%) females (male to female ratio = 1.5:1).
Mean age was 45 years (range, 6 to 71). A total of
53 patients (77.9%) had underlying diseases, in-
cluding 16 cases of tuberculosis (23.5%), 13 of
COPD (19.1%), 6 cases of bronchiectasis, 6 of lung
cancer (8.2%), 4 cases of inflammatory pseudo tu-
mor, 3 of pulmonary cysts, 2 cases each of lung ab-
scess, gout and diabetes, and 1 case each of severe
pneumonia, empyema, bronchopleural fistula, idio-
pathic thrombocytopenic purpura, systemic lupus
erythematosus, drug-induced neutropenia, pemphi-
gus, acute immunodeficiency syndrome (AIDS), 
cytomegalovirus infection, and asthma. Four cases
had used corticosteroids for more than 6 months.
Three cases had received lung surgery previously,
and 2 cases chemotherapy previously. The incidence
of other diseases was 89.5% in pulmonary as-
pergillosis patients and 52.6% in pulmonary crypto-
coccosis patients, the difference between them being
significant (p < 0.05). Details are given in Table I.
Diagnostic methods 
Of the 68 patients, 38 (55.9%) were diagnosed by
open-lung biopsy; 15 cases (22.1%) were con-
firmed by transbronchial biopsy; 11 cases (16.2%)
were diagnosed by computerized tomography (CT)
guided percutaneous needle biopsy. Among the 14
cases of non-surgical pulmonary aspergillosis, 11
patients (78.6%) were confirmed by transbronchial
biopsy. Among the 10 cases of non-surgical pul-
monary cryptococcosis, 8 patients (80.0%) were
confirmed by CT guided percutaneous needle biop-
sy. Details are given in Table II.
Clinical manifestations 
The main symptoms of the patients were as follows:
cough in 51 cases (75.0%); expectoration in 38 cas-
es (55.9%), with blood in sputum in 18 cases, white
phlegm in 12 cases, and purulent sputum in 8 cas-
es; hemoptysis in 25 cases (36.8%); fever in 20 cas-
es (29.4%); chest pain and shortness of breath in 5
cases; headache, nausea and vomiting in 3 cases.
Only 6 patients (11.1%) were asymptomatic.
Notably, 20 out of the 38 apergillosis patients
(52.6%) had hemoptysis while only 3 out of the 19
pulmonary cryptococcosis cases (15.8%) had he-
moptysis. The incidence of hemoptysis in pul-
monary aspergillosis was significantly higher than
in the other groups of pulmonary mycosis (p <
0.05). The main signs included: ipsilateral de-































cases (44.1%); focal wet rales in 13 cases (19.1%);
superficial lymphadenectasis in 8 cases. Details are
given in Table III.
Radiographic characteristics 
Type: masses or nodule lesions in 52 cases (76.5%),
patchy lesions in 10 cases (14.7%), cavity formation
in 15 cases (22.0%), and diffuse miliary nodules in
1 case. In the 38 pulmonary aspergillosis cases, 13
patients (34.2%) showed the formation of cavities,
while only 2 cases (6.7%) showed cavities in other
pulmonary mycosis. Pulmonary aspergillosis pa-
tients had a significantly higher incidence of cavity
formation than other pulmonary mycosis patients (p
< 0.05). Details are given in Table IV.
Site: 9 cases (13.2%) involved bilateral lung; 33
cases (48.5%) involved the right lung, 26 cases
(38.2%) the left lung. The upper lobes were mainly
involved in pulmonary aspergillosis, while the right
lower lobe was mainly involved in pulmonary crypto-
coccosis. 
Specific signs: ‘air-crescent sign’ was observed in 6
cases of pulmonary aspergillosis (15.8%), whereas
‘halo sign’ was found in 9 (23.7%) pulmonary as-
pergillosis patients and 6 (31.5%) pulmonary cryp-
tococcosis patients. The lesions of pulmonary cryp-
tococcal patients were located in the peripheral
lung fields close to the pleura. Other signs included:
lung hilum or mediastinal lymphadenectasis in 25
cases (36.7%), pleural thickening and adhesion in 9
cases and pleural effusion in 8 cases (Figures 1-4). 
Diagnosis of pulmonary mycosis by bronchoscopy
Bronchoscopy was performed in 38 cases (55.9%).
The results showed endobronchial polypoid, cauli-
flower-like lumps in 10 cases, purulent inflamma-
tion in 3 cases, and bronchial stenosis in 3 cases. 
Misdiagnosis
Of the 68 patients, 51 (75.0%) were misdiagnosed
before pathological examination. Specifically, 21
cases (30.9%) were misdiagnosed as pulmonary tu-
berculosis, 19 (27.9%) as lung cancer, and 11 cases
(16.2%) as bacterial infection and bronchiectasis.
Treatment and prognosis 
Of the 68 patients, 38 cases (55.9%) underwent sur-
gical resection of pulmonary lesions. One case suf-
TABLE I: DEMOGRAPHIC DATA FOR 68 PATIENTS WITH PULMONARY MYCOSIS    
Pulmonary  Pulmonary Pulmonary Pulmonary Pulmonary Pulmonary Total
aspergillosis cryptococcosis histoplasmosis sporotrichosis actinomycosis candidiasis
n = 38 n = 19 n = 4 n = 1 n = 1 n = 5
Male/female 1/1 3/1 1/4 — — 4/1 1.5/1
Mean age 47.7 39.2 32.7 49 58 51 45.0
Underlying diseases 34 10 3 1 0 5 53
TABLE II: DIAGNOSTIC METHODS USED IN THE 68 PATIENTS WITH PULMONARY MYCOSIS    
Pulmonary  Pulmonary Pulmonary Pulmonary Pulmonary Pulmonary Total
aspergillosis cryptococcosis histoplasmosis sporotrichosis actinomycosis candidiasis
n = 38 n = 19 n = 4 n = 1 n = 1 n = 5
Open-lung biopsy 24 9 3 0 0 2 38
Transbronchial biopsy 11 1 0 1 1 1 15
CT guided percutaneous 2 8 0 0 0 1 11
needle biopsy
TABLE III: MAIN CLINICAL MANIFESTATIONS OF 68 PATIENTS WITH PULMONARY MYCOSIS    
Pulmonary  Pulmonary Pulmonary Pulmonary Pulmonary Pulmonary Total
aspergillosis cryptococcosis histoplasmosis sporotrichosis actinomycosis candidiasis
n = 38 n = 19 n = 4 n = 1 n = 1 n = 5
Cough 30 13 2 1 1 4 51
Expectoration 24 7 1 1 1 4 38
Fever 5 8 1 1 1 4 20
Hemoptysis 20 3 0 0 0 2 25
Asymptomatic 1 3 2 0 0 0 6
Percussion dullness 19 5 0 1 1 4 30
Focal wet rales 8 0 1 1 0 3 13
Superficial lymphadenectasis 2 3 1 1 0 1 8
MRM 281












fered from cryptococcal meningitis after the opera-
tion. Twenty-five cases (36.8%) received systemic
antifungal therapy, 20 cases (29.4%) experiencing
complete or partial responses, and 5 cases showing
no response or disease progression. Three cases
were lost to follow up, and 2 cases died.
Adverse effects of antifungal drugs 
After antifungal drug therapy, adverse effects oc-
curred in 12 cases, among which 10 had received
monotherapy and 2 combined treatment. After flu-
conazole therapy, 2 cases demonstrated an elevated
serum aminotransferase level and 1 case developed
hypokalemia. After amphotericin B therapy, fever
and chills occurred in 3 cases, and phlebitis oc-
curred in 1 case. After itraconazole therapy, 2 cases
developed hypokalemia and 1 case demonstrated
elevated serum bilirubin level. For the 2 cases of
combined treatment with fluconazole and ampho-
tericin B, 1 case showed renal dysfunction while
another case demonstrated chills, fever, and elevat-
ed serum aminotransferase level. 
DISCUSSION
Fungi are widespread in nature and the majority of
them are opportunistic pathogens which may be
present in healthy people and cause disease when
the host immunity is lower or defective. Aspergillus
has been reported as the main pathogen accounting
for 54.8% of deep fungal diseases, the lung being
involved in all Aspergillus infections, while crypto-
coccosis accounted for 19.4% of fungal infections
and mainly involved the central nervous system and
lung [5]. Chen et al. reported that the most preva-
lent forms of pulmonary mycosis were pulmonary
aspergillosis (57%), pulmonary cryptococcosis
(21%), and pulmonary candidiasis (14%) [6].
Consistent with this study, here we have shown that
the most prevalent organisms isolated from pul-
monary mycosis were pulmonary aspergillosis
(55.9%), pulmonary cryptococcosis (27.9%) and
pulmonary candidiasis (7.4%). The incidence of
pulmonary candidiasis is also very high [7].
However, these lesions are mainly diffuse and the
pathological results were not readily available in
our pathologic examination. Only when the diffuse
lesions merge into masses or nodule lesions can we
obtain the pathological results by surgical opera-
tions, transbronchial biopsy or CT guided percuta-
neous needle biopsy [7,8]. 
Final diagnosis of pulmonary mycosis is well
known to depend on pathological examination.
Given that thoracotomy may cause damage to the
patients and increase the risk of complications, it is
important to develop less invasive methods for
pathological examination. The non-operative 
methods of diagnosis vary depending on the
pathogens. Pulmonary aspergillosis is mainly con-
firmed by transbronchial biopsy while pulmonary
cryptococcosis is mainly confirmed by CT guided
percutaneous lung puncture. Pulmonary aspergillo-
sis usually involves the bronchi, which makes trans-
bronchial biopsy the best mode for the diagnosis.
The main manifestation of pulmonary crypto -
coccosis is subpleural nodules. CT guided percuta-
neous needle biopsy of peripheral lung lesions is
important to confirm the diagnosis of pulmonary
cryptococcosis [9]. 
Depending on the pathogens, the clinical manifes-
tations, imaging features and management of pul-
monary mycosis differ. First, there are different
predilection sites for different forms of pulmonary
mycosis. Pulmonary aspergillosis occurs in the up-
per lobes similarly as for tuberculosis, while pul-
monary cryptococcosis occurs in the right lower
lobe with lesions located in peripheral lung fields
close to the pleura. Second, cavity formation and
hemoptysis are more likely to develop in pul-
monary aspergillosis than in other forms of pul-
TABLE IV: CHEST IMAGING FEATURES OF 68 PATIENTS WITH PULMONARY MYCOSIS    
Pulmonary  Pulmonary Pulmonary Pulmonary Pulmonary Pulmonary Total
aspergillosis cryptococcosis histoplasmosis sporotrichosis actinomycosis candidiasis
n = 38 n = 19 n = 4 n = 1 n = 1 n = 5
Masses or nodule lesions 28 16 3 1 1 3 52
Patchy lesions 6 2 0 0 0 2 10
Cavity formation 13 2 0 0 0 0 15
Diffuse miliary nodules 0 1 0 0 0 0 1
FIGURE 1: REPRESENTATIVE RADIOGRAPHIC PICTURES OF
PULMONARY ASPERGILLOSIS
CT examination had earlier shown the ‘halo sign’; with the progres-
sion of disease, 1 week later, it showed ‘air-crescent sign’.































monary mycosis. In our 38 pulmonary aspergillosis
cases, 13 patients (34.2%) showed the formation of
cavities, while 20 patients (52.6%) showed hemop-
tysis. Third, in this study 9 (23.7%) pulmonary as-
pergillosis patients and 6 (31.5%) pulmonary cryp-
tococcosis patients showed the ‘halo sign’. It is im-
portant to note that ‘halo sign’ is not specific for
pulmonary aspergillosis. In fact, non-infectious dis-
eases such as tumor invasion or organized pneumo-
nia could lead to hemorrhagic pulmonary nodules,
therefore also causing the imaging change. Other
infectious diseases which cause hemorrhagic pul-
monary nodules may also show ‘halo sign’.
Therefore, we could not exclude other diseases when
the ‘halo sign’ was shown in chest imaging [10].
Surgical resection and antifungal drugs are the main
treatment methods for pulmonary mycosis. In our
report, 38 patients (55.9%) received surgical resec-
tion, and most of them had no recurrence with only
1 patient suffering from cryptococcal meningitis 3
months after the operation. Twenty-five cases
(36.8%) received drug treatment and 20 of them
experienced a complete or partial response.
Satisfactory therapy can be obtained by both anti-
fungal and surgical treatment. Pulmonary as-
pergillosis patients in the following situations
should be considered for surgical resection: focal
lesions associated with hemoptysis; failure of anti-
fungal treatment; life-threatening hemoptysis or le-
sions close to large vessels. It has been proposed
that antifungal therapy is not required after surgi-
cal resection [11,12]. In this study, 24 patients
with pulmonary aspergillosis received only surgi-
cal resection and none of them showed complica-
tions or recurrence. Fourteen patients received an-
tifungal therapy and 10 of them used itraconazole.
Nine patients experienced complete or partial re-
sponses. It has been confirmed that sequential
therapy with itraconazole is well tolerated, safe
and effective in invasive pulmonary aspergillosis
[13]. According to the guidelines of the Infectious
Diseases Society of America [9], pulmonary crypto-
coccosis patients with mild or moderate clinical
symptoms should be treated with fluconazole,
FIGURE 2: REPRESENTATIVE RADIOGRAPHIC PICTURES OF
PULMONARY CRYPTOCOCCOSIS
CT examination showed the "nodule lesion" (upper) and the "mass
lesion" and the "cavity formation, air-crescent sign" (down).
FIGURE 3: REPRESENTATIVE PATHOLOGICAL PICTURE OF
PULMONARY ASPERGILLOSIS
Fungal mycelium was stained with light blue. 
The hyphae had similar thickness and were with branching, showing
an acute angle of about 45°.
FIGURE 4: REPRESENTATIVE PATHOLOGICAL PICTURE OF
PULMONARY CRYPTOCOCCOSIS
Cryptococcal granuloma and round spores were found on PAS stai-
ning (+).
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while patients with severe clinical symptoms
should be treated with amphotericin B. If antifun-
gal drugs fail or the lesions cannot be distin-
guished from the tumor, surgical resection needs
to be considered. In view of the recurrence of
cryptococcal meningitis in some patients, sys-
temic antifungal therapy is recommended after
surgical resection [14]. 
Our results confirm the importance of systemic an-
tifungal therapy following surgery.
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